SVA NASDAQ
Sinovac Biotech Ltd.
1W: +0.0%
1M: +0.0%
3M: +0.0%
$6.47
Last traded 2025-03-10 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$106M
+113.5% ▲
5Y CAGR: +67.9%
Capital Expenditures
$146M
+63.9% ▲
5Y CAGR: +91.8%
Free Cash Flow
-$42M
+96.4% ▲
Dividends Paid
$328M
-24.7% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$3.0B
+58.9% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $65M | $185M | $14.5B | $88M | -$258M |
| Depreciation & Amort. | $5M | $4M | $87M | $157M | $145M |
| Stock-Based Comp. | $3M | $10M | $8M | $0 | $0 |
| Change in Working Capital | -$28M | $283M | $461M | -$1.1B | $278M |
| Other Non-Cash Items | -$49K | $8M | $73M | -$760K | -$135M |
| Operating Cash Flow | $39M | $479M | $15.4B | -$771M | $106M |
| — Investing Activities — | |||||
| Capital Expenditures | -$11M | -$128M | -$720M | -$403M | -$146M |
| Acquisitions (Net) | $21K | $541M | -$14M | $9M | $39K |
| Investment Purchases | -$51M | -$202M | -$8.8B | -$11.7B | -$8.4B |
| Investment Sales | $19M | $125M | $6.6B | $6.3B | $5.6B |
| Other Investing | $0 | -$541M | -$31M | -$35M | $0 |
| Investing Cash Flow | -$42M | -$205M | -$3.0B | -$5.8B | -$2.9B |
| — Financing Activities — | |||||
| Net Debt Issuance | $261K | $33M | -$26M | -$4M | $239M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | -$1.9B | -$263M | -$328M |
| Other Financing | $1M | $17M | $4M | $26M | $12M |
| Financing Cash Flow | $2M | $593M | -$1.9B | -$241M | -$76M |
| Net Change in Cash | -$2M | $894M | $10.6B | -$7.3B | -$3.0B |
| Cash End of Period | $156M | $1.1B | $11.6B | $4.3B | $1.3B |
| Free Cash Flow | $28M | $352M | $14.6B | -$1.2B | -$42M |